13 research outputs found
Participant flow diagram.
<p>Randomisation and flow of participants over a period of 6 months for adults (cohorts 1 to 5), adolescents (cohort 6; 13–17 years), and children (cohort 7; 6–12 years). Similar dose groups are matched with shading (light grey, 3 × 10<sup>6</sup> PFU; dark grey, 2 × 10<sup>7</sup> PFU). GP, glycoprotein; ELISA, enzyme-linked immunosorbent assay; PFU, plaque-forming units; rVSV, recombinant vesicular stomatitis virus.</p
Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.
<p>Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.</p
Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.
<p>Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.</p
Viral load in saliva for children and adolescents.
<p>rVSV<b>Δ</b>G-ZEBOV-GP (rVSV) RNA copy numbers in saliva presented as log10 rVSV RNA copies/ml from day 2 and 7 (d2 and d7) post-injection in adolescents and children vaccinated with 2 × 10<sup>7</sup> PFU. The broken line denotes the limit of quantitation, and the dotted line denotes the limit of detection. About 67% (12/18) and 30% (6/20) adolescents and children, respectively, had samples above the limit of quantification at day 7. *P < 0.05; **P < 0.01.PFU, plaque-forming units.</p
Glycoprotein antibody distribution by age group: Comparison of distribution of ZEBOV-GP IgG antibodies (AEU/ml) measured by USAMRIID ZEBOV-GP ELISA for dose 2 Ă— 10<sup>7</sup> PFU administered to children, adolescents, and adults from day 0, 28, 56, 84, and 180.
<p>Data were not available for children and adolescents at D84. P < 0.05 indicates a statistical difference in ZEBOV-GP IgG between children, adolescents, and adults. AEU, arbitrary enzyme-linked immunosorbent assay units; ELISA, enzyme-linked immunosorbent assay; GP, glycoprotein; PFU, plaque-forming units; USAMRIID, US Army Medical Research Institute of Infectious Diseases; ZEBOV, Zaire Ebola virus.</p
Endpoint geometric mean titres measured by USAMRIID ZEBOV-GP ELISA in adults with and without baseline specific antibodies.
<p>Endpoint geometric mean titres measured by USAMRIID ZEBOV-GP ELISA in adults with and without baseline specific antibodies.</p
Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by whole-virion ELISA in adults.
<p>Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by whole-virion ELISA in adults.</p
Reactogenicity to rVSVΔG-ZEBOV-GP vaccine until day 28 post-vaccination.
<p>Reactogenicity to rVSVΔG-ZEBOV-GP vaccine until day 28 post-vaccination.</p
Antibody responses to whole-virion ELISA (AEU/ml) by age group: Comparison of geometric mean concentration of IgG antibodies for children, adolescents, and adults vaccinated with the 2 Ă— 10<sup>7</sup> PFU dose at day 0, 28, and 56.
<p>P < 0.05 indicates a statistical difference in antibody concentrations between age groups at the measured time points. AEU, arbitrary enzyme-linked immunosorbent assay units; ELISA, enzyme-linked immunosorbent assay; PFU, plaque-forming units; ZEBOV, Zaire Ebola virus.</p